Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biotech company focusing on chronic organ diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Han Ying, PhD, will present a company overview on September 10, 2024, at 8:30 AM ET.
The presentation will be available via live webcast on Gyre's website Events and Presentations page. For those unable to attend the live session, a replay will be accessible afterward. This event provides an opportunity for investors to gain insights into Gyre's operations, clinical development programs, and future prospects in the biotechnology sector.
Gyre Therapeutics (Nasdaq: GYRE), un'azienda biotech in fase commerciale che si concentra sulle malattie croniche degli organi, ha annunciato la sua partecipazione alla 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright. Il CEO Han Ying, PhD, presenterà una panoramica dell'azienda il 10 settembre 2024, alle 8:30 AM ET.
La presentazione sarà disponibile tramite webcast in diretta sulla pagina eventi e presentazioni del sito web di Gyre. Per coloro che non possono partecipare alla sessione in diretta, sarà disponibile un riassunto successivo. Questo evento offre un'opportunità per gli investitori di ottenere informazioni sulle operazioni di Gyre, sui programmi di sviluppo clinico e sulle prospettive future nel settore biotech.
Gyre Therapeutics (Nasdaq: GYRE), una empresa biotecnológica en etapa comercial que se enfoca en enfermedades crónicas de órganos, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversión H.C. Wainwright. El CEO Han Ying, PhD, presentará una visión general de la empresa el 10 de septiembre de 2024, a las 8:30 AM ET.
La presentación estará disponible a través de una transmisión en vivo en la página de Eventos y Presentaciones del sitio web de Gyre. Para aquellos que no puedan asistir a la sesión en vivo, un replay estará accesible posteriormente. Este evento ofrece una oportunidad para que los inversores obtengan información sobre las operaciones de Gyre, sus programas de desarrollo clínico y sus perspectivas futuras en el sector biotecnológico.
Gyre Therapeutics (Nasdaq: GYRE), 만성 장기 질환에 중점을 둔 상업 단계의 생명공학 기업이 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO 한잉 박사가 2024년 9월 10일 오전 8시 30분 ET에 회사 개요를 발표할 예정입니다.
발표는 라이브 웹캐스트를 통해 이용 가능하며 Gyre 웹사이트의 이벤트 및 발표 페이지에서 시청할 수 있습니다. 실시간 세션에 참석할 수 없는 분들을 위해 재생본이 제공될 예정입니다. 이 이벤트는 투자자들에게 Gyre의 운영, 임상 개발 프로그램 및 생명공학 분야의 미래 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Gyre Therapeutics (Nasdaq: GYRE), une entreprise biopharmaceutique en phase commerciale axée sur les maladies organiques chroniques, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. Le PDG Han Ying, PhD, présentera un aperçu de l'entreprise le 10 septembre 2024 à 8h30 ET.
La présentation sera disponible en streaming en direct sur la page Événements et Présentations du site web de Gyre. Pour ceux qui ne peuvent pas assister à la session en direct, une rediffusion sera accessible par la suite. Cet événement offre aux investisseurs l'occasion d'obtenir des informations sur les opérations de Gyre, ses programmes de développement clinique et ses perspectives d'avenir dans le secteur biopharmaceutique.
Gyre Therapeutics (Nasdaq: GYRE), ein biotechnologisches Unternehmen im kommerziellen Stadium, das sich auf chronische Organerkrankungen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. CEO Han Ying, PhD wird am 10. September 2024 um 8:30 Uhr ET eine Unternehmensübersicht präsentieren.
Die Präsentation wird über ein Live-Webcast verfügbar sein auf der Seite für Veranstaltungen und Präsentationen der Gyre-Website. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird anschließend ein Wiedergabe verfügbar sein. Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in Gyres Betrieb, klinische Entwicklungsprogramme und zukünftige Aussichten im Biotechnologiesektor zu gewinnen.
- None.
- None.
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 8:30 AM ET (5:30 AM PT).
The live webcast will be available on the Events and Presentations page of Gyre’s website. A webcast replay will be accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
For Investors:
Stephen Jasper
FAQ
When is Gyre Therapeutics (GYRE) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Gyre Therapeutics (GYRE) at the investment conference?
How can investors access Gyre Therapeutics' (GYRE) presentation at the H.C. Wainwright conference?
What is the focus of Gyre Therapeutics' (GYRE) clinical development programs?
Is Gyre Therapeutics (GYRE) a commercial-stage company?
